Medicus Pharma Shares Jump 10% as Antev Acquisition Adds Late-Stage Prostate Drug to Pipeline Shares of Medicus Pharma Ltd. (NASDAQ: MDCX) are up 10% today following Monday’s announcement of a definitive agreement to acquire UK-based clinical-stage bio

Medicus Pharma Ltd. (NASDAQ: #MDCX)shares surged 10% following its acquisition of Antev Ltd., bringing a late-stage prostate cancer drug into its pipeline.
#MedicusLtd
Read more: prismmarketview.com/medicus-phar...

Medicus Pharma Eyes $250M Equine Cancer Market with FDA Submission for Novel D-MNA Patch Medicus Pharma Ltd. (Nasdaq: MDCX) has submitted a product development plan to the U.S. Food and Drug Administration to advance its doxorubicin-containing micro

#MDCX is targeting the $250M equine cancer market with its novel D-MNA patch, now submitted to the FDA. A big step forward in veterinary oncology innovation!
#MedicusLtd
prismmarketview.com/medicus-phar...